DURECT and Sandoz Signs $293 Million Agreement for POSIMIR (SABER-Bupivacaine)
DURECT announced that it has signed a $293 Million Agreement with Sandoz to develop and market DURECT's POSIMIR (SABER-Bupivacaine) in the United States.
According to the terms of…
Read More...
Read More...